Advertisement
Research Article

Reporting Bias in Drug Trials Submitted to the Food and Drug Administration: Review of Publication and Presentation

  • Kristin Rising,

    Affiliation: School of Medicine, University of California San Francisco, San Francisco, California, United States of America

    ยค Current address: Department of Internal Medicine, Boston Medical Center, Boston, Massachusetts, United States of America

    X
  • Peter Bacchetti,

    Affiliation: Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, United States of America

    X
  • Lisa Bero mail

    To whom correspondence should be addressed. E-mail: berol@pharmacy.ucsf.edu

    Affiliation: Clinical Pharmacy and Health Policy, University of California San Francisco, San Francisco, California, United States of America

    X
  • Published: November 25, 2008
  • DOI: 10.1371/journal.pmed.0050217

Reader Comments (4)

Post a new comment on this article

Correction

Posted by plosmedicine on 31 Mar 2009 at 00:32 GMT

Author: Nisha Doshi
Position: Publications Assistant
Institution: PLoS Medicine
E-mail: ndoshi@plos.org
Submitted Date: November 25, 2008
Published Date: November 25, 2008
This comment was originally posted as a “Reader Response” on the publication date indicated above. All Reader Responses are now available as comments.

Please note that there are a few corrections to the results section that we've been made aware of since the full manuscript was accepted for publication.

On page 5 of the PDF, under the heading “Discrepancies in Primary Outcome Reporting,” the “155/179” outcomes that were also found in the NDAs should read “138/179.” On page 7, under the heading “Discrepancies in Conclusions,”"35 of 36" including unknowns should read "34 of 36."

A formal correction is forthcoming.

No competing interests declared.